Showing 11,641 - 11,660 results of 100,274 for search '(( 5 step decrease ) OR ( 5 ((teer decrease) OR (((a decrease) OR (mean decrease)))) ))', query time: 1.76s Refine Results
  1. 11641

    Association of Matrix Metalloproteinase-3 -1171(5A>6A) Polymorphism with Cancer Risk: A Meta-Analysis of 41 Studies by Xin Yang (104842)

    Published 2014
    “…</p><p>Conclusion</p><p>This meta-analysis suggests that the -1171(5A>6A) polymorphism in MMP3 promoter region is not associated with overall cancer risk, but it may contribute to decreased cancer risk in Asian population when compared with Caucasian population and significantly reduce the risk of gastrointestinal cancer.…”
  2. 11642

    3’UTR luciferase assay and Western blotting identify Integrin alpha V and N-WASP as relevant regulatory targets of miR-142-3p. by Alexander Schwickert (835514)

    Published 2015
    “…The migration position of molecular weight markers relative to Integrin-αV and N-WASP is shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0143993#pone.0143993.s004" target="_blank">S4 Fig</a>.…”
  3. 11643
  4. 11644
  5. 11645
  6. 11646
  7. 11647
  8. 11648
  9. 11649

    β<sub>12</sub>-Borophene/Graphene Heterostructure as a High-Performance Anode Material for Li-Ion Batteries by Sorour Faramarzi (18552936)

    Published 2024
    “…Impressively, the calculated specific capacity reached 907 mAh/g, outperforming other 2D materials and heterostructures. The combination of a graphene layer not only ensures dynamical stability but also provides the adsorption energy of lithiumon the β<sub>12</sub>-borophene layer, simultaneously decreasing the diffusion barrier energy in comparison with the β<sub>12</sub>-borophene monolayer. …”
  10. 11650
  11. 11651
  12. 11652

    Table_1_Atypical neurological manifestations in anti-IgLON5 disease: a case report.docx by Yun Chen (279569)

    Published 2024
    “…<p>Anti-IgLON5 disease is a recently discovered autoimmune encephalopathy with sleep disorder as a hallmark in the majority of reported cases. …”
  13. 11653

    Effects of conivaptan on brain water content (BWC), blood-brain-barrier (BBB) disruption, plasma and urine sodium and osmolality. by Emil Zeynalov (596088)

    Published 2015
    “…Following MCAO, Evans Blue (EB) extravasation index (I/C) was increased in vehicle treated mice, and reduced in conivaptan treated mice, naïve, n = 5, vehicle, n = 8, Conivaptan 0.2 mg, n = 8. (C, D) Conivaptan treatment of 0.2 mg resulted in an elevation of plasma sodium and osmolality, and decreased urine sodium and osmolality due to aquaresis. …”
  14. 11654
  15. 11655
  16. 11656
  17. 11657
  18. 11658
  19. 11659
  20. 11660